Effects of small molecule inhibitor SW033291 on hepatic ischemia-reperfusion injury in mice

Hepatic ischemia-reperfusion injury (IRI) is an important factor in the recovery of liver function and prognosis after liver surgery. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) small molecule inhibitor SW033291 is thought to play an important role in promoting tissue regeneration. The aim of this study was to investigate the effect of 15-PGDH on ischemia-reperfusion injury in mouse liver. In this study, mice in the administered group showed lower necrosis and inflammation than control mice, partly due to reduced macrophage and neutrophil infiltration in liver tissue, as well as reduced serum or tissue levels of pro-inflammatory cytokines and oxidative stress. In addition, mice in the administered group showed increased post-injury reparation due to IRI-induced injury compared to control mice. CONCLUSION: The small molecule inhibitor SW033291 played a better role in preventing hepatic ischemia-reperfusion injury in mice and may be a potential option to prevent the development and progression of hepatic I/R.